Page last updated: 2024-11-01

niclosamide and Infections, Coronavirus

niclosamide has been researched along with Infections, Coronavirus in 5 studies

Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.

Research Excerpts

ExcerptRelevanceReference
"Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic."5.62Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. ( Brunaugh, AD; Ding, L; Seo, H; Seo, SH; Smyth, HDC; Warnken, Z, 2021)
"The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics."2.66Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ( Li, H; Shi, PY; Xu, J; Zhou, J, 2020)
"Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic."1.62Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. ( Brunaugh, AD; Ding, L; Seo, H; Seo, SH; Smyth, HDC; Warnken, Z, 2021)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's5 (100.00)2.80

Authors

AuthorsStudies
Jeon, S1
Ko, M1
Lee, J1
Choi, I1
Byun, SY1
Park, S1
Shum, D1
Kim, S1
Wang, Y1
Huang, H1
Li, D1
Zhao, C1
Li, S1
Qin, P1
Li, Y2
Yang, X1
Du, W1
Li, W1
Xu, J1
Shi, PY1
Li, H1
Zhou, J1
Gupta, SP1
Brunaugh, AD1
Seo, H1
Warnken, Z1
Ding, L1
Seo, SH1
Smyth, HDC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409]231 participants (Actual)Interventional2020-04-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for niclosamide and Infections, Coronavirus

ArticleYear
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
    ACS infectious diseases, 2020, 05-08, Volume: 6, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug R

2020
Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
    Current topics in medicinal chemistry, 2020, Volume: 20, Issue:26

    Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus

2020

Other Studies

3 other studies available for niclosamide and Infections, Coronavirus

ArticleYear
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiop

2020
Identification of niclosamide as a novel antiviral agent against porcine epidemic diarrhea virus infection by targeting viral internalization.
    Virologica Sinica, 2023, Volume: 38, Issue:2

    Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Coronavirus Infections; Niclosamide; Porcine epidem

2023
Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.
    PloS one, 2021, Volume: 16, Issue:2

    Topics: Administration, Inhalation; Animals; Antiviral Agents; Cell Line; Coronavirus Infections; COVID-19 D

2021